Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer

[1] Al-Hussaini M(2004)WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma Histopathology 44 109-115

[2] Stockman A(2011)The role of targeted therapy in ovarian cancer Eur J Cancer 47 S116-S130

[3] Foster H(2008)Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival Clin Cancer Res 14 89-96

[4] McCluggage WG(2007)Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas J Clin Oncol 25 2281-2287

[5] Banerjee S(1989)Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials Br J Cancer 59 650-653

[6] Kaye S(1989)Expression of a human multidrug resistance gene in ovarian carcinomas Cancer Res 49 5062-5065

[7] Bartel F(2000)Angiogenesis in ovarian cancer Baillieres Best Pract Res Clin Obstet Gynaecol 14 901-918

[8] Jung J(2011)Overview of anti-angiogenic agents in development for ovarian cancer Gynecol Oncol 121 230-238

[9] Bohnke A(2011)Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2473-2483

[10] Gradhand E(2001)A prognostic model for ovarian cancer Br J Cancer 85 944-952

[1] Al-Hussaini M(2004)WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma Histopathology 44 109-115

[2] Stockman A(2011)The role of targeted therapy in ovarian cancer Eur J Cancer 47 S116-S130

[3] Foster H(2008)Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival Clin Cancer Res 14 89-96

[4] McCluggage WG(2007)Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas J Clin Oncol 25 2281-2287

[5] Banerjee S(1989)Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials Br J Cancer 59 650-653

[6] Kaye S(1989)Expression of a human multidrug resistance gene in ovarian carcinomas Cancer Res 49 5062-5065

[7] Bartel F(2000)Angiogenesis in ovarian cancer Baillieres Best Pract Res Clin Obstet Gynaecol 14 901-918

[8] Jung J(2011)Overview of anti-angiogenic agents in development for ovarian cancer Gynecol Oncol 121 230-238

[9] Bohnke A(2011)Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2473-2483

[10] Gradhand E(2001)A prognostic model for ovarian cancer Br J Cancer 85 944-952